熱門資訊> 正文

Lifeward最新外骨骼设备获得FDA批准

2025-03-13 23:22

Lifeward (NASDAQ:LFWD) stock soared on Thursday after it has received 510((k)) FDA clearance for its new personal exoskeleton device, the ReWalk 7.
LFWD is up 42% in morning trade.
The company said that the seventh generation of the ReWalk, a wearable exoskeleton that allows individuals with spinal cord injury to stand and walk again, will begin selling in the United States as soon as the product is available.

More on Lifeward

Lifeward Ltd. (LFWD) Q4 2024 Earnings Call Transcript
Lifeward Non-GAAP EPS of -$0.38 misses by $0.05, revenue of $7.55M misses by $0.29M
Lifeward CEO Larry Jasinski to step down
Seeking Alpha’s Quant Rating on Lifeward
Historical earnings data for Lifeward

推薦文章

風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。